Alzheimer’s vaccine enters human trials aiming to stop disease before symptoms begin

John E. Kaye
- Published
- News, Technology

A new Alzheimer’s vaccine designed to stop the disease before symptoms appear is entering human clinical trials in the United States
The treatment, called Duvax, targets both amyloid-beta and tau—the two key proteins linked to the development of Alzheimer’s—and is intended for people at risk of the disease but who have not yet shown cognitive decline.
Alzheimer’s is the most common cause of dementia, affecting an estimated 55 million people worldwide, with 10 million new cases diagnosed each year.
In the UK alone, nearly one million people are living with dementia, and Alzheimer’s accounts for around two-thirds of those cases.
Despite decades of research, no treatment has yet been shown to prevent the disease before symptoms begin.
Unlike existing therapies that attempt to slow progression once memory and cognition are already affected, Duvax is being developed as a secondary prevention therapy.
It is designed for use during the “preclinical” stage, when abnormal proteins are already accumulating in the brain but before irreversible neurological damage has set in.
The vaccine uses an immunotherapy approach to train the body’s immune system to recognise and clear harmful forms of amyloid and tau.
Its use is guided by blood tests that can detect these early pathological changes—allowing for timely intervention and the possibility of halting the disease in its tracks.
The Phase 1 trial will assess the safety and immunogenicity of Duvax in humans. It is backed by a $3 million grant from the US National Institutes of Health (NIH), awarded through the agency’s SBIR Fast-Track programme.
An initial portion of the grant has been released to begin the trial, with the remainder expected later in 2025.
Nuravax, a clinical-stage biotech company focused on neurodegenerative disorders, is leading the development, regulatory work and manufacturing of the vaccine, which is licensed from the non-profit Institute for Molecular Medicine (IMM). The underlying technology is based on IMM’s MultiTEP platform, a modular vaccine system adaptable to DNA, RNA and recombinant protein formats.
If successful, Duvax would become the first vaccine to target both of Alzheimer’s core drivers in people with no symptoms, offering a potential shift from treatment to prevention in one of the most challenging areas of modern medicine.
Roman Kniazev, CEO of Nuravax, said: “This SBIR grant is a powerful endorsement of our mission to clinically validate and advance Duvax as a first-in-class vaccine for Alzheimer’s prevention.
“While IMM laid the scientific foundation, our focus at Nuravax is on translating that innovation into real-world impact. This funding enables us to move Duvax into clinical trials in the U.S. and brings us one step closer to delivering it as preventive therapy for individuals at risk – before symptoms begin.”
The need for early intervention has grown increasingly urgent as the global population ages. By 2050, the number of people living with dementia is expected to more than triple, reaching over 150 million. While some new drugs have been approved in recent years to target amyloid plaques in diagnosed patients, their effects are modest, and treatment must begin early to have any measurable benefit.
Dr Michael Agadjanyan, Vice President of the Institute for Molecular Medicine and Head of Immunology, said the trial represented a critical turning point after years of foundational research.
“The Phase 1 trial, supported by this SBIR grant awarded to our development and commercialization partner, Nuravax, marks a critical step in translating years of foundational research at IMM into a potential clinical breakthrough,” he said.
“Based on strong preclinical data, we at IMM expect Duvax to elicit a robust immune response against both Aβ and tau pathologies, an approach that could fundamentally shift the paradigm of Alzheimer’s treatment from symptomatic and disease-modifying treatment (DMT) to secondary preventive therapy for cognitively unimpaired people at risk of disease.”
Main photo: Anna Shvets/Pexels
Sign up to The European Newsletter
RECENT ARTICLES
-
XTI Aerospace launches Founders Club for TriFan 600 backers
-
New ranking measures how Europe’s biggest retailers report on sustainability
-
CEOs who endured childhood disasters show greater appetite for risky debt, study finds
-
Galorath appoints Julia Gerth to lead EMEA and APAC sales in global expansion push
-
UK to restart trade talks with China after seven-year pause
-
AM Best affirms Active Re’s ‘A’ rating for third year running
-
UK contract recruitment rises despite slowdown in permanent hiring
-
Forterro buys Spain’s Inology to expand southern Europe footprint
-
Singapore student start-up wins $1m Hult Prize for education platform
-
Nigeria’s startup scene takes global stage as Lagos hosts inaugural GITEX NIGERIA
-
City and Gulf investors track golf’s newest global venture
-
UK businesses increase AI investment despite economic uncertainty, Barclays index finds
-
French CEOs warn politics and geopolitics now threaten bottom lines, ESSEC study finds
-
Study links female-dominated classrooms to higher lifetime earnings for women
-
Inside London’s £1bn super-hotel with £20k penthouses, private butlers and a gilded eagle
-
Kia America hits record monthly sales as EV demand surges
-
Trump family’s crypto debut adds $5bn to fortune amid ethics row
-
Warren Buffett turns 95 – the secrets behind a $130 billion fortune
-
Most game developers now using AI in their workflows, Google Cloud study finds
-
BlackRock takes $89m stake in Freedom Holding, emerging as second-largest shareholder
-
Welcome to Britain’s most exclusive founders’ network with £1M entry bar
-
Portugal’s GR22 crowned Europe’s most rewarding hiking trail
-
Music faces a bum note without elephant dung, new research warns
-
Fermi America secures $350m in financing led by Macquarie Group
-
Cambodia to rename key highway after Donald Trump for brokering peace deal